AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications Philadelphia, Pennsylvania, USA - October 27-30, 2017

被引:0
|
作者
Simoneaux, R. [1 ]
Font, H. [2 ]
机构
[1] Clarivate Analyt, Philadelphia, PA 19130 USA
[2] Clarivate Analyt, Barcelona, Spain
关键词
Tipifarnib; Dabrafenib/trametinib/navitoclax; Tazemetostat; ASTX-660; RG-7386; AZ-4374; AZD-1390; T-025; DS-5010; TAK-164; ABC-131;
D O I
10.1358/dof.2017.042.12.2739619
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer Conference (AACR-NCI-EORTC) began almost 30 years ago as the European-based EORTC-NCI meetings. In 1999, partnership with the AACR was initiated, primarily to respond to the rapid developments that were taking place in the fields of molecular biology and genetics that gave rise to the increase in the number of potential targets for cancer therapeutics. The presenting organizations all seek to foster communication within the global scientific community so that researchers can share their findings with fellow scientists across all subdisciplines of cancer research and drug discovery. The 2017 conference was attended by more than 1,500 scientists, researchers and clinicians from government, academic and industrial institutions. Details on research from these internationally based attendees were delivered in more than 500 oral and poster presentations.
引用
收藏
页码:793 / 800
页数:8
相关论文
共 24 条